BMS’ Cobenfy sees steady start, eyes stronger growth ahead
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their
AI-powered cardiometabolic wellness platform for India’s workforce
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Subscribe To Our Newsletter & Stay Updated